About Aopia Biosciences
Founded in 2026, Aopia Biosciences, Inc. develops bioengineering technologies for extracellular vesicle (EV) and exosome isolation. The company supports biomedical research, diagnostic development and therapeutic applications. Its technologies are designed to improve EV recovery, purity and integrity from biological samples. Automated and scalable workflows help researchers generate consistent results with minimal manual handling. Applications include cell biology, biomarker discovery, translational research and the development of EV-based therapeutics.
Aopia Biosciences offers technologies including the VanoFlow™ EV Isolation Cassette and the NanoEX™ platform for EV processing and isolation. These systems support extracellular vesicle purification across research and development workflows. They are suitable for both laboratory-scale studies and larger therapeutic development programmes. The company also provides supporting services and technical resources for EV isolation and characterisation.
Europa Biosite’s subsidiaries distribute for Aopia Biosciences in Belgium, Ireland, Luxembourg, Netherlands, Switzerland and the United Kingdom.